HPV52 positive can be vaccinated against cervical cancer, but the vaccine has a preventive role, not a curative one. HPV52 positive is a high-risk HPV infection, which may cause cervical cancer if it persists, but the incubation period varies from a few months to several years, depending on the number of viruses and the specific immunity of the body. If there is no abnormality, anti-viral drugs can be administered vaginally, or oral drugs can be given to enhance the body’s resistance, such as anti-HPV bioprotein dressing for vaginal application, or Rebieson continuous vaginal application for 30 times as a course of treatment, and the treatment will be stopped for more than 1 month. HPV review to see if HPV is eliminated. In addition, patients should pay attention to strengthening the body’s resistance, pay attention to sexual hygiene, as well as the usual cleanliness of the vulva.